sprite-icon-arrow-left
sprite-icon-caret-down
sprite-icon-caret-right
sprite-icon-chevron-down
sprite-icon-close
sprite-icon-down-arrow
sprite-icon-download
sprite-icon-external-link
Facebook
sprite-icon-hamburger
sprite-icon-instagram
LinkedIn
sprite-icon-magnify
sprite-icon-pause
sprite-icon-play
sprite-icon-plus
sprite-icon-pound
sprite-icon-quote
sprite-icon-search
sprite-icon-triangle-right
Twitter
sprite-icon-up-arrow
Vimeo
sprite-numiko-logo
Skip to main content
Please enable JavaScript in your web browser to get the best experience.
Close
Go to Cancer Research Horizons homepage
Main navigation
About us
Expand submenu for About us
Our network
Our partners
Our governance
Our leadership
Cancer Research Horizons Board
Therapeutic Innovation Board
Our annual reviews
Our gender and ethnicity pay gap report
Our expertise
Expand submenu for Our expertise
Therapeutic innovation
Our drug discovery science
Our approach to therapeutic innovation
Our drug discovery hotspots
Our therapeutic alliance model
Our partnership with Abcam
Functional Genomics Centre
Research translation
Intellectual property
Routes to translation
Research tools
Entrepreneurial programmes
Start your entrepreneurial journey
Advanced programmes for entrepreneurs
Programmes to grow your startup
Cancer Research Horizons Seed Fund
New ventures
Set up and build your startup
Licensing opportunities
Collaborate with us
Expand submenu for Collaborate with us
Researchers
Research translation
Therapeutic innovation
Entrepreneurial programmes
New ventures
Cancer Research Horizons Seed Fund
Our project development fund
Data Innovation Awards
Pharma & biotech
How we partner with industry
Our network
Medtech
Data partnerships
Our portfolio
Our alliance model
Investors
How we partner with investors
Our network
Our expertise
Our startups
Cancer Research Horizons Seed Fund
Our impact
Expand submenu for Our impact
Our success stories
Our annual reviews
Our portfolio
Expand submenu for Our portfolio
Our pipeline
Our startups
Our licensing opportunities
Research tools
News & features
Expand submenu for News & features
Our news
Our blog
Our media
Menu
Search
About us
Our network
Our partners
Our governance
Our leadership
Cancer Research Horizons Board
Therapeutic Innovation Board
Our annual reviews
Our gender and ethnicity pay gap report
Our expertise
Therapeutic innovation
Our drug discovery science
Our approach to therapeutic innovation
Our drug discovery hotspots
Our therapeutic alliance model
Our partnership with Abcam
Functional Genomics Centre
Research translation
Intellectual property
Routes to translation
Research tools
Entrepreneurial programmes
Start your entrepreneurial journey
Advanced programmes for entrepreneurs
Programmes to grow your startup
Cancer Research Horizons Seed Fund
New ventures
Set up and build your startup
Licensing opportunities
Collaborate with us
Researchers
Research translation
Therapeutic innovation
Entrepreneurial programmes
New ventures
Cancer Research Horizons Seed Fund
Our project development fund
Data Innovation Awards
Pharma & biotech
How we partner with industry
Our network
Medtech
Data partnerships
Our portfolio
Our alliance model
Investors
How we partner with investors
Our network
Our expertise
Our startups
Cancer Research Horizons Seed Fund
Our impact
Our success stories
Our annual reviews
Our portfolio
Our pipeline
Our startups
Our licensing opportunities
Research tools
News & features
Our news
Our blog
Our media
Back
to previous menu
Cancer research at the academic/industry interface
How Cancer Research Horizons is innovating through its academic and industry interface
Join Steve Wedge, our Chief Scientific Officer and Mike Waring, our Head of Academic Medicinal Chemistry for this podcast with Drug Discovery World to find out how our Newcastle Drug Discovery site combines the strength of our enhanced drug discovery with that of our academic network.